MannKind (MNKD)
Commercializes Afrezza, FUROSCIX and V-Go while manufacturing Tyvaso DPI for United Therapeutics.
$3.48
After hours0.00 (0.00%)
At close$3.48(−0.57%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51 | 58 | 66 | 72 | 70 | 77 | 78 | 77 | 82 | 112 | 90 | 109 |
| Cost of revenue | 14 | 18 | 19 | 20 | 18 | 20 | 18 | 21 | 20 | 24 | 22 | 30 |
| Gross profit | 37 | 40 | 48 | 52 | 52 | 57 | 61 | 56 | 62 | 88 | 68 | 80 |
| 32 | 33 | 31 | 35 | 39 | 31 | 39 | 51 | 43 | 96 | 71 | 80 | |
| Research & development | 10 | 9 | 10 | 12 | 13 | 11 | 11 | 14 | 14 | 28 | 17 | 18 |
| 24 | 21 | 22 | 24 | 24 | 24 | 25 | 32 | 29 | 58 | 54 | 58 | |
| Selling & marketing | 13 | 11 | 12 | 11 | 13 | 0 | 0 | 0 | 15 | 0 | 0 | 0 |
| General & administrative | 11 | 10 | 11 | 13 | 11 | 0 | 0 | 0 | 14 | 0 | 0 | 58 |
| Other expenses | −2 | 3 | −1 | −1 | 2 | −4 | 3 | 5 | 0 | 10 | 0 | 4 |
| Operating income | 5 | 8 | 17 | 17 | 13 | 26 | 22 | 5 | 19 | −8 | −3 | 0 |
| −3 | −5 | −6 | −18 | 0 | −18 | −9 | −4 | −11 | −13 | −13 | −19 | |
| Interest income | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 4 | 1 | 0 |
| Interest expense | 5 | 5 | 9 | 13 | 8 | 7 | 11 | 6 | 7 | 13 | 12 | 12 |
| Other non-operating income | −2 | 0 | −3 | 5 | −8 | 11 | −2 | −2 | 4 | 0 | 1 | −7 |
| Income before tax | 2 | 3 | 11 | −2 | 13 | 8 | 14 | 1 | 8 | −21 | −16 | −19 |
| Income tax expense | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | −5 | 0 | 0 |
| Net income from continuing operations | 2 | 1 | 11 | −2 | 12 | 7 | 13 | 1 | 8 | −16 | −17 | −19 |
| Net income | 2 | 1 | 11 | −2 | 12 | 7 | 13 | 1 | 8 | −16 | −17 | −19 |
| EPS, basic | $0.01 | $0.01 | $0.04 | −$0.01 | $0.04 | $0.03 | $0.04 | $0.00 | $0.03 | −$0.05 | −$0.05 | −$0.06 |
| EPS, diluted | $0.01 | $0.00 | $0.03 | −$0.01 | $0.04 | $0.03 | $0.04 | $0.00 | $0.03 | −$0.05 | −$0.05 | −$0.06 |
| Weighted average shares, basic | 269 | 270 | 270 | 273 | 275 | 279 | 303 | 305 | 307 | 306 | 308 | 309 |
| Weighted average shares, diluted | 269 | 324 | 325 | 273 | 285 | 291 | 321 | 311 | 312 | 314 | 308 | 309 |
| EBITDA | 8 | 10 | 22 | 13 | 24 | 19 | 27 | 10 | 18 | −3 | 2 | 13 |
| Depreciation & amortization | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 5 | 6 | 6 |
| EBIT | 7 | 8 | 20 | 11 | 21 | 16 | 24 | 7 | 15 | −8 | −4 | 7 |